Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Maspero, Jorge F (Fundación CIDEA)
Castro, Mario (University of Kansas School of Medicine)
Hanania, Nicola A. (Baylor College of Medicine)
Ford, Linda B (Asthma & Allergy Center)
Halpin, David M G (College of Medicine and Health)
Jackson, David J (King's College London)
Daizadeh, Nadia (Sanofi-Syntelabo)
Djandji, Michel (Sanofi-Syntelabo)
Mitchell, Colin P (Sanofi-Syntelabo)
Crikelair, Nora (Regeneron Pharmaceuticals. Inc)
Jacob-Nara, Juby A (Sanofi-Syntelabo)
Deniz, Yamo (Regeneron Pharmaceuticals. Inc)
Rowe, Paul J (Sanofi-Syntelabo)
Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2022
Description:	9 pàg.
Abstract:	Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. Dupilumab efficacy in patients with varying disease burden (defined by baseline OCS dose) has not been assessed. Objective: This post hoc analysis of VENTURE evaluated dupilumab efficacy across subgroups defined by baseline OCS dose. Methods: The OCS dose, proportion no longer needing OCS at week 24, annualized severe exacerbation rate, and least squares mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second at week 24 were evaluated in VENTURE patients with OCS-dependent severe asthma receiving dupilumab 300 mg every 2 weeks versus placebo, categorized by a baseline OCS dose of less than 10 mg/d or 10 or more mg/d. Results: Dupilumab reduced daily OCS dose from baseline at week 24 in both dose groups. In dupilumab-/placebo-treated patients with a baseline OCS dose of less than 10 mg/d and 10 or more mg/d, 72%/42% and 37%/23% stopped OCS by week 24 (P < . 01/P < . 05), respectively. Dupilumab significantly reduced the annualized severe exacerbation rate by 71% and 48% (P < . 01/P < . 05). At week 24, dupilumab improved pre- and post-bronchodilator forced expiratory volume in 1 second in patients in both dose groups. Conclusions: In patients with OCS-dependent severe asthma receiving lower or higher baseline OCS doses, dupilumab significantly reduced the OCS dose and improved the likelihood of no longer requiring OCS while also reducing exacerbations and improving lung function.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Adrenal Cortex Hormones/therapeutic use ; Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; Asthma ; Bronchodilator Agents/therapeutic use ; Double-Blind Method ; Humans ; Injections, Subcutaneous ; Steroids/therapeutic use ; Treatment Outcome ; Interleukin-4 ; Interleukin-13 ; Exacerbation ; Chronic oral corticosteroids ; Lung function ; Dupilumab ; SDG 3 - Good Health and Well-being
Published in:	The Journal of allergy and clinical immunology. In practice, Vol. 10 Núm. 7 (July 2022) , p. 1835-1843, ISSN 2213-2201

DOI: 10.1016/j.jaip.2022.03.020
PMID: 35398549

9 p, 430.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles